Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:David_Chang
|
| gptkbp:collaboratesWith |
gptkb:Servier
gptkb:Cellectis |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
allogeneic CAR-T cell therapies
|
| gptkbp:founded |
2018
|
| gptkbp:founder |
gptkb:David_Chang
gptkb:Arie_Belldegrun |
| gptkbp:headquarters_location |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Allogene Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:IPODate |
October 2018
|
| gptkbp:notableProduct |
gptkb:ALLO-501
gptkb:ALLO-647 gptkb:ALLO-715 |
| gptkbp:numberOfEmployees |
200-500
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
solid tumors
hematologic cancers |
| gptkbp:servesArea |
global
|
| gptkbp:specialty |
immuno-oncology
gene therapy |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ALLO
|
| gptkbp:website |
https://www.allogene.com/
|
| gptkbp:bfsParent |
gptkb:Alexandria_Venture_Investments
|
| gptkbp:bfsLayer |
6
|